Brief: Xintela Stem Cell Product Assessed As Safe In Study
13/10/2023 14:27
Oct 13 (Reuters) - Xintela AB XINT.ST :
* XINTELA’S STEM CELL PRODUCT, XSTEM, HAS BEEN ASSESSED AS
SAFE AT
ALL DOSE LEVELS IN KNEE OSTEOARTHRITIS CLINICAL STUDY
Source text for Eikon: ID:nMFN7TgC5y
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))